조혈모세포 이식 환자의 돌발성 구역·구토에 대한 항구토제 사용 현황
Evaluation of Antiemetic Therapy for Breakthrough Nausea and Vomiting in Patients with Hematopoietic Stem Cell Transplantation
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The patients receiving hematopoietic stem cell transplantation (HSCT) are known to have a high incidence ofbreakthrough nausea and vomiting due to the conditioning regimen. The purpose of this study was to evaluate the adequacy ofantiemetic therapy for breakthrough nausea and vomiting in patients receiving HSCT and to propose an effective treatment regimen. Methods: We retrospectively reviewed the electronic medical records of 109 adult patients. The collected data were used to identify(1) antiemetic and dosing regimens prescribed for controlling breakthrough nausea and vomiting, (2) the rate of patients whodeveloped breakthrough nausea and vomiting, and (3) the percent of antiemetics prescribed on the day of symptom onset. Basedon the National Comprehensive Cancer Network guideline, we assessed the suitability of antiemetics for breakthrough nausea andvomiting, and prescription timing. Results: All patients were prescribed pro re nata antiemetics. About 40.0%, 41.4%, and 18.6% ofpatients were using one, two, and three or more additional drugs for breakthrough nausea and vomiting, respectively. The mostfrequently administered drugs were intravenous metoclopramide (43.8%) and granisetron patch (36.2%). Breakthrough nausea andvomiting occurred in 87 patients (79.1%) and they developed symptoms 320 cases. About 220 cases (68.8%) were treated withadditional antiemetics on the day of symptom onset and the rate of symptom resolution was only 10.3% (9 patients). Conclusion:The breakthrough nausea and vomiting in patients receiving HSCT occurred very frequently and was hard to control, thus requiringmore rapid and aggressive treatments.
Abstract
Background: The patients receiving hematopoietic stem cell transplantation (HSCT) are known to have a high incidence ofbreakthrough nausea and vomiting due to the conditioning regimen. The purpose of this study was to evaluate the adequacy ofantiemetic therapy for breakthrough nausea and vomiting in patients receiving HSCT and to propose an effective treatment regimen. Methods: We retrospectively reviewed the electronic medical records of 109 adult patients. The collected data were used to identify(1) antiemetic and dosing regimens prescribed for controlling breakthrough nausea and vomiting, (2) the rate of patients whodeveloped breakthrough nausea and vomiting, and (3) the percent of antiemetics prescribed on the day of symptom onset. Basedon the National Comprehensive Cancer Network guideline, we assessed the suitability of antiemetics for breakthrough nausea andvomiting, and prescription timing. Results: All patients were prescribed pro re nata antiemetics. About 40.0%, 41.4%, and 18.6% ofpatients were using one, two, and three or more additional drugs for breakthrough nausea and vomiting, respectively. The mostfrequently administered drugs were intravenous metoclopramide (43.8%) and granisetron patch (36.2%). Breakthrough nausea andvomiting occurred in 87 patients (79.1%) and they developed symptoms 320 cases. About 220 cases (68.8%) were treated withadditional antiemetics on the day of symptom onset and the rate of symptom resolution was only 10.3% (9 patients). Conclusion:The breakthrough nausea and vomiting in patients receiving HSCT occurred very frequently and was hard to control, thus requiringmore rapid and aggressive treatments.
참고문헌 (19)
- Bliss JM, "The impact of nausea and vomiting upon quality of life measures", Br J Cancer Suppl, 19(suppl), pp.S14~S22 (1992)
- Fox-Geiman MP, "Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation", Biol Blood Marrow Transplant, 7, pp.596~603 (2001)[DOI]
- Kamakshi R, "Chemotherapy-Induced Nausea and Vomiting: Optimizing Prevention and Management", Am Health Drug Benefits, 5(4), pp.232~240 (2012)
- Navari RM, "Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting", Biomed Res Int, 2015, pp.595894~ (2015)
- Fernandez-Ortega P, "Chemotherapyinduced nausea and vomiting in clinical practice: impact on patients' quality of life", Support Care Cancer, 20, pp.3141~3148 (2012)[DOI]
- "National Comprehensive Cancer Network (NCCN) guideline Antiemesis Version.2"[URL]
- Aapro M, "The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)", Ann Oncol, 23, pp.1986~1992 (2012)[DOI]
- Manal Z, "Assessing prescribing patterns for the prevention of chemotherapy-induced nausea and vomiting in the national center for cancer care and research", Saudi Pharm J, 23, pp.381~387 (2015)[DOI]
- Karin J, "Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations", The Oncologist, 12, pp.1143~1150 (2007)[DOI]
- Boccia RV, "Use of transdermal and intravenous granisetron and the ability of the Hesketh score to assess nausea and vomiting induced by multiday chemotherapy", Cancer Manag Res, 4, pp.171~176 (2012)
- "Power and Sample Size Programs"[URL]
- 이효진, "임상 연구에서 연구 표본수의 산출", 대한 견주관절 학회지, 16(1), pp.53~57 (2013), 대한견주관절학회
- Navari RM, "The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy", Support Care Cancer, 21(6), pp.1655~1663 (2013)[DOI]
- Seher A, "Prevention of Chemotherapy-Induced Nausea and Vomiting", US Pharm, 39(3), pp.7~11 (2014)
- Tuca A, "Use of granisetron transdermal system in the prevention of chemotherapy induced nausea and vomiting: a review", Cancer Manag Res, 2, pp.1~12 (2010)
- Tamura K, "Breakthrough chemother- apy- induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan", Int J Clin Oncol, 22, pp.405~412 (2017)[DOI]
- Grunberg S, "Incidence of chemotherapy- induced nausea and emesis after modern antiemetics", Cancer, 100(10), pp.2261~2268 (2004)[DOI]
- "Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0"[URL]
- Ramy E, "Pharmacist-driven management of chemotherapy induced nausea and vomiting in hospitalized adult oncology patients: retrospective comparative study", Inov Pharm, 2(3) (2011)